can restore TRAIL pathways in XIAP-overexpressing cells. Finally, Scott Lowe (Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, USA) elegantly showed that in MLL/ENLexpressing leukemia cells, a single shRNA to Myb can cure chemoresistance in AML, arguing that survival addiction in human cancers can be overcome by selectively targeting cell death pathways.
Several sessions also focused on the role of autophagy in both survival and death pathways in metazoan cells. Eileen White (Cancer Institute of New Jersey, New Brunswick, NJ, USA) introduced the apparent paradox that autophagy has both a tumor-promoting role in cancer by permitting dormancy under conditions of metabolic stress and a tumor-suppressive mechanism. The tumor-suppressing activity of autophagy is multifactorial and complex, and is highlighted by the fact that when autophagy is inhibited in tumor cells, damaged proteins and organelles lead to genetic instability and DNA damage. A series of talks subsequently followed addressing both pro-survival and pro-death end points for autophagy (Jeff McLean, Queens College, Flushing, NY, USA), and another general theme emerged that many microorganisms hijack apoptotic pathways for their replication and survival. Finally, Junying Yuan (Harvard University, Cambridge, MA, USA) gave an overview of the emerging field of necroptosis, a caspase-independent form of death that is dependent on the RIP1 kinase, and is strongly inhibited by necrostatins.
The meeting also highlighted the rapid pace of biomedical research in South Africa and neighboring countries. Several scientists participated from various institutions, and enthusiastically embraced collaborations and sharing of information. Stonard Kanyanda (AuTEK Biomed, Mintek, Johannesburg, South Africa) described efforts to isolate novel apoptotic modulators from various plants and animals in South Africa. This highly interactive meeting opened new avenues of research and collaborations, and provided a culturally enriching experience for all.
